Document Detail

Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment.
MedLine Citation:
PMID:  18492363     Owner:  NLM     Status:  MEDLINE    
Intermittent vaginal administration of recombinant human FSH (rhFSH), for ovarian stimulation in IVF employing the concept of uterine first-pass effect and mesotherapy, was investigated. Injection of rhFSH (437 IU, counted as six ampoules) was carried out every 3 days into the vaginal mucosa of 66 participants receiving IVF treatment between November 2004 and August 2006. The primary outcomes were number of mature oocytes, number of good grade embryos, and term live birth rate (>/=37 weeks gestation). On average, 2.94 days of injection and 16.35 ampoules of rhFSH were required to achieve proper follicular growth. Although fewer mature oocytes (5.27 +/- 3.69) were retrieved, the number of good grade embryos (3.05 +/- 1.95), number of embryos transferred (2.66 +/- 1.70), pregnancy rate per cycle started [37.9%; 95% confidence interval (CI), 27.1-49.9], implantation rate (25.5%; 95% CI, 18.0-33.0), and term live birth rate (31.8 %; 95% CI, 21.8-43.8) were comparable with conventional IVF treatments in this clinic.
Chao-Chin Hsu; Chao-Tien Hsu; Qing Gu; Shan-Tair Wang
Related Documents :
16488903 - Perifollicular vascularity in poor ovarian responders during ivf.
6724003 - Pregnancy following in vitro fertilization and embryo transfer using pure human serum a...
20027043 - Reliability of fetal sex determination using maternal plasma.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Reproductive biomedicine online     Volume:  16     ISSN:  1472-6491     ISO Abbreviation:  Reprod. Biomed. Online     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-05-21     Completed Date:  2008-08-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101122473     Medline TA:  Reprod Biomed Online     Country:  England    
Other Details:
Languages:  eng     Pagination:  617-20     Citation Subset:  IM    
Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, Tainan 701, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Birth Rate
Drug Administration Routes
Follicle Stimulating Hormone / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Ovarian Follicle / drug effects*,  growth & development
Ovulation Induction*
Patient Compliance
Recombinant Proteins / administration & dosage,  adverse effects,  pharmacology,  therapeutic use
Reg. No./Substance:
0/Recombinant Proteins; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of gonadotrophin stimulation for assisted reproductive technology on ovarian ageing and menop...
Next Document:  What can we expect if we measure hormones in eumenorrhoeic infertile patients?